Application of astragaloside IV and compound thereof in preparation of medicine for treating polycystic ovarian syndrome and medicine

Abstract

The invention belongs to the technical field of medicines for treating polycystic ovarian syndrome, and particularly relates to application of astragaloside IV and a compound thereof in preparation of a medicine for treating polycystic ovarian syndrome and the medicine. The compound is prepared from the following raw materials: mannitol, vitamin B3 and vitamin B9, wherein the mass ratio of the mannitol to the vitamin B3 to the vitamin B9 is (0.5-1): (0.5-1): 1; the mass ratio of the astragaloside IV to the compound is 1: (2-4). The mannitol, the vitamin B3 and the vitamin B9 are used for activating a PPAR gamma channel, increasing the relative expression quantity of PPAR gamma and inhibiting proliferation of human ovarian granular cells. And the mannitol, the vitamin B3, the vitamin B9 and the astragaloside IV are mixed for use, so that the effect is optimal.

Description

Technical Field

[0001] This invention belongs to the field of polycystic ovary syndrome (PCOS) drug technology, specifically relating to the application of astragaloside IV (AS-IV) and its compound in the preparation of PCOS drugs and the drugs themselves. Background Technology

[0002] Polycystic ovary syndrome (PCOS) is a complex reproductive endocrine and metabolic disorder characterized by reproductive dysfunction and abnormal glucose metabolism. Its causes include both genetic and environmental factors. Genetic factors include genes related to insulin resistance, while environmental factors include high-sugar diets, bisphenol A (BPA) exposure, and chronic stress. The main clinical manifestations of PCOS include oligomenorrhea or amenorrhea, hirsutism, obesity, and infertility. Some patients may develop acanthosis nigricans or bilateral ovarian enlargement. The disease can lead to metabolic disorders such as type 2 diabetes and hypertension, and increases the risk of endometrial cancer. These symptoms and their severity may vary from person to person.

[0003] Currently, treatment strategies for polycystic ovary syndrome (PCOS) include drug intervention and dietary control. Drug intervention includes medications such as GLP-1 receptor agonists, letrozole, and dihydroartemisinin, while dietary control involves choosing low-sugar, low-calorie foods. The main mechanisms of action of these drugs include suppressing appetite, reducing weight, lowering blood sugar, and inhibiting fat absorption. These drug treatments are mostly limited to those targeting anovulatory infertility, menstrual disorders, or hyperandrogenemia. However, comprehensively improving ovarian function, especially improving the morphology of polycystic ovaries and the distribution of ovarian granulosa cells, remains a clinical challenge.

[0004] Studies have shown that astragaloside IV (AS-IV) has antioxidant, anti-inflammatory, antibacterial and anti-atherosclerotic properties. It can inhibit the epithelial-mesenchymal transition of podocytes in glomerular diseases and improve the morphological changes of cardiomyocytes induced by high glucose in diabetic cardiomyopathy. It can activate autophagy through the PPARγ pathway, thereby improving ovarian function in rats with polycystic ovary syndrome, and inhibit the proliferation of human ovarian granulosa cells and promote their apoptosis.

[0005] However, the efficacy of astragaloside IV alone still needs to be improved. Summary of the Invention

[0006] To address the aforementioned technical problems, this invention provides the application of astragaloside IV (AS-IV) and its compound in the preparation of drugs for polycystic ovary syndrome, as well as the drug itself.

[0007] The first objective of this invention is to provide the application of astragaloside IV and its compound in the preparation of a drug for the treatment of polycystic ovary syndrome. The compound is composed of the following raw materials: mannitol, vitamin B3, and vitamin B9, in a mass ratio of 0.5~1:0.5~1:1; and the mass ratio of astragaloside IV to the compound is 1:2~4.

[0008] Preferably, in the application of the above-mentioned astragaloside IV and its compound in the preparation of drugs for the treatment of polycystic ovary syndrome, the mass ratio of astragaloside IV to the compound is 1:2.

[0009] Preferably, in the application of the above-mentioned astragaloside IV and its compound in the preparation of a drug for the treatment of polycystic ovary syndrome, the drug is an aqueous solution.

[0010] Preferably, in the application of the above-mentioned astragaloside IV and its compound in the preparation of drugs for the treatment of polycystic ovary syndrome, the concentration of the drug is 20 μg / mL to 60 μg / mL.

[0011] Preferably, the above-mentioned astragaloside IV and its compound are used in the preparation of a drug for treating polycystic ovary syndrome, wherein the drug is a drug for treating polycystic ovary syndrome in rats.

[0012] Preferably, the above-mentioned astragaloside IV and its compound are used in the preparation of a drug for the treatment of polycystic ovary syndrome, wherein the drug is a drug that improves insulin levels, glucose levels, luteinizing hormone levels, follicle-stimulating hormone levels and testosterone levels.

[0013] Preferably, the above-mentioned astragaloside IV and its compound are used in the preparation of a drug for treating polycystic ovary syndrome, wherein the drug is a drug that inhibits the proliferation of human ovarian granulosa cells.

[0014] Preferably, in the preparation of a drug for treating polycystic ovary syndrome, the above-mentioned astragaloside IV and its compound are used, wherein the drug uses the compound and the astragaloside IV as active ingredients.

[0015] A second objective of this invention is to provide a therapeutic formulation for polycystic ovary syndrome, using the aforementioned astragaloside IV and the aforementioned compound as active ingredients, and formulated with pharmaceutically permissible excipients.

[0016] Preferably, in the above-mentioned treatment formulation for polycystic ovary syndrome, the excipients include one or more of sodium carboxymethyl cellulose, sodium alginate, polyvinyl alcohol, and polyoxyethylene.

[0017] Compared with the prior art, the present invention has the following beneficial effects: This invention provides the application of astragaloside IV and its compound in the preparation of a drug for treating polycystic ovary syndrome (PCOS). The compound is composed of mannitol, vitamin B3, and vitamin B9 in a mass ratio of 0.5-1:0.5-1:1; the mass ratio of astragaloside IV to the compound is 1:2-4. Mannitol, vitamin B3, and vitamin B9 are newly discovered substances capable of inhibiting human ovarian granulosa cells. Their combination with astragaloside IV enhances their ability to kill human ovarian granulosa cells. Mannitol, vitamin B3, and vitamin B9 activate the PPARγ pathway, increase the relative expression of PPARγ, and inhibit the proliferation of human ovarian granulosa cells. The optimal effect is achieved when mannitol, vitamin B3, vitamin B9, and astragaloside IV are used in combination. Attached Figure Description

[0018] Figure 1 This is the result of a fasting insulin test.

[0019] Figure 2 This is the result of a fasting glucose test.

[0020] Figure 3 This is the result of the luteinizing hormone test.

[0021] Figure 4 This is the result of the follicle-stimulating hormone (FSH) test.

[0022] Figure 5 This is the result of a test for testosterone.

[0023] Figure 6 The results show the relative expression levels of PPARγ.

[0024] Figure 7 This is the result of the cell viability test.

[0025] Figure 8 This is the second result of the cell viability test. Detailed Implementation

[0026] To enable those skilled in the art to better understand and implement the technical solutions of the present invention, the present invention will be further described below in conjunction with specific embodiments and accompanying drawings.

[0027] Unless otherwise specified, all reagents used in this invention are commercially available, and all methods used are conventional techniques in the art.

[0028] The inventive concept of this invention is as follows: Although existing technologies show that astragaloside IV can inhibit the proliferation of human ovarian granulosa cells, the inhibitory effect needs to be improved.

[0029] This invention provides the application of astragaloside IV and its compound in the preparation of a drug for the treatment of polycystic ovary syndrome. The compound is composed of the following raw materials: mannitol, vitamin B3, and vitamin B9, with a mass ratio of 0.5~1:0.5~1:1; and the mass ratio of astragaloside IV to the compound is 1:2~4.

[0030] Astragaloside IV, CAS number 84687-43-4, was purchased from Unicore (Shanghai) Life Science Co., Ltd. It can activate autophagy through the PPARγ pathway, thereby improving ovarian function in rats with polycystic ovary syndrome, and inhibiting the proliferation of human ovarian granulosa cells while promoting their apoptosis.

[0031] Mannitol is a newly discovered substance in this invention that can inhibit the proliferation of human ovarian granulosa cells and kill them. The combination of mannitol and astragaloside IV further enhances the ability to kill human ovarian granulosa cells, suggesting that the combination has a better therapeutic effect on polycystic ovary syndrome.

[0032] Mannitol, vitamin B3, and vitamin B9 were used to activate the PPARγ pathway, increase the relative expression of PPARγ, and inhibit the proliferation of human ovarian granulosa cells. Although the inhibitory effect of mannitol, vitamin B3, and vitamin B9 on the proliferation of human ovarian granulosa cells was weaker when used alone than that of astragaloside IV alone, they all showed an inhibitory effect on the proliferation of human ovarian granulosa cells compared to the blank control group containing sterile deionized water.

[0033] This invention conducted experiments using a mixture of mannitol, vitamin B3, vitamin B9, and astragaloside IV. The results showed that, compared to the blank control group containing sterile deionized water, the mixture exhibited the best effect and the most significant increase in the relative expression level of PPARγ. Replacing vitamin B3 and vitamin B9 with other B vitamins, or replacing mannitol with other alcohols, resulted in no difference in effect compared to using astragaloside IV alone. This demonstrates the specificity of the combination of mannitol, vitamin B3, vitamin B9, and astragaloside IV; the raw materials and dosages should not be arbitrarily changed.

[0034] Specific embodiments of the present invention are as follows.

[0035] Example 1 A treatment for polycystic ovary syndrome includes astragaloside IV and its compound, said compound being composed of the following ingredients: mannitol, vitamin B3, and vitamin B9, wherein the mass ratio of mannitol, vitamin B3, and vitamin B9 is 0.5:0.5:1; and the mass ratio of astragaloside IV to the compound is 1:2.

[0036] The preparation method is as follows: Mannitol, vitamin B3, and vitamin B9 were thoroughly mixed in a mass ratio of 0.5:0.5:1 to obtain a compound. Then, astragaloside IV was mixed with the compound in a mass ratio of 1:2.

[0037] Example 2 A treatment for polycystic ovary syndrome includes astragaloside IV and its compound, wherein the compound is composed of the following ingredients: mannitol, vitamin B3, and vitamin B9, wherein the mass ratio of mannitol, vitamin B3, and vitamin B9 is 0.7:0.5:1; and the mass ratio of astragaloside IV to the compound is 1:2.

[0038] The preparation method is as follows: Mannitol, vitamin B3, and vitamin B9 were thoroughly mixed in a mass ratio of 0.7:0.5:1 to obtain a compound. Then, astragaloside IV was mixed with the compound in a mass ratio of 1:2.

[0039] Example 3 A treatment for polycystic ovary syndrome includes astragaloside IV and its compound, wherein the compound is composed of the following ingredients: mannitol, vitamin B3, and vitamin B9, wherein the mass ratio of mannitol, vitamin B3, and vitamin B9 is 1:0.5:1; and the mass ratio of astragaloside IV to the compound is 1:2.

[0040] The preparation method is as follows: Mannitol, vitamin B3, and vitamin B9 were thoroughly mixed in a mass ratio of 1:0.5:1 to obtain a compound. Then, astragaloside IV was mixed with the compound in a mass ratio of 1:2.

[0041] Example 4 A treatment for polycystic ovary syndrome includes astragaloside IV and its compound, said compound being composed of the following ingredients: mannitol, vitamin B3, and vitamin B9, with a mass ratio of mannitol, vitamin B3, and vitamin B9 of 0.5:0.7:1; and a mass ratio of astragaloside IV to the compound of 1:2.

[0042] The preparation method is as follows: Mannitol, vitamin B3, and vitamin B9 were thoroughly mixed in a mass ratio of 0.5:0.7:1 to obtain a compound. Then, astragaloside IV was mixed with the compound in a mass ratio of 1:2.

[0043] Example 5 A treatment for polycystic ovary syndrome includes astragaloside IV and its compound, wherein the compound is composed of the following ingredients: mannitol, vitamin B3, and vitamin B9, wherein the mass ratio of mannitol, vitamin B3, and vitamin B9 is 0.5:1:1; and the mass ratio of astragaloside IV to the compound is 1:2.

[0044] The preparation method is as follows: Mannitol, vitamin B3, and vitamin B9 were thoroughly mixed in a mass ratio of 0.5:1:1 to obtain a compound. Then, astragaloside IV was mixed with the compound in a mass ratio of 1:2.

[0045] Example 6 A treatment for polycystic ovary syndrome includes astragaloside IV and its compound, said compound being composed of the following ingredients: mannitol, vitamin B3, and vitamin B9, with a mass ratio of mannitol, vitamin B3, and vitamin B9 of 0.5:0.5:1; and a mass ratio of astragaloside IV to the compound of 1:4.

[0046] The preparation method is as follows: Mannitol, vitamin B3, and vitamin B9 were thoroughly mixed in a mass ratio of 0.5:0.5:1 to obtain a compound. Then, astragaloside IV was mixed with the compound in a mass ratio of 1:4.

[0047] Single-factor control 1 One of the drugs used to treat polycystic ovary syndrome is astragaloside IV.

[0048] Single-factor control 2 Mannitol is a medication used to treat polycystic ovary syndrome.

[0049] Single-factor control 3 A medication for treating polycystic ovary syndrome is vitamin B3.

[0050] Single-factor control 4 A medication for treating polycystic ovary syndrome is vitamin B9.

[0051] Blank control group: sterile deionized water.

[0052] The key differences between the above embodiments and single-factor control 1 are shown in Table 1.

[0053] Table 1. Dosage Relationship of Each Component Note: "-" indicates that there is no data for this item.

[0054] I. Animal Experiments Several 8-week-old SD rats, weighing 220g±25g, were collected. The SD rats were randomly divided into the following groups: blank control group, model group, Example 1 group, Example 2 group, Example 3 group, Example 4 group, Example 5 group, Example 6 group, single-factor control group 1, single-factor control group 2, single-factor control group 3, and single-factor control group 4. There were 6 rats in each group.

[0055] SD rats were acclimatized for 3 days in an environment of 22℃ and 60% humidity with a 12-hour light / 12-hour dark cycle.

[0056] The blank control group was not injected with dehydroepiandrosterone (DHEA), but instead received an equal volume of sterile water.

[0057] The model group received subcutaneous injections of dehydroepiandrosterone at a dose of 60 mg / kg / day for 20 days.

[0058] In Example 1, dehydroepiandrosterone (DHEA) was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; additionally, the treatment drug from Example 1 was injected daily at a dose of 20 mg / kg / day.

[0059] In Example 2, dehydroepiandrosterone was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; additionally, the treatment drug from Example 2 was injected daily at a dose of 20 mg / kg / day.

[0060] In Example 3, dehydroepiandrosterone was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; additionally, the treatment drug from Example 3 was injected daily at a dose of 20 mg / kg / day.

[0061] In Example 4, dehydroepiandrosterone was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; additionally, the treatment drug from Example 4 was injected daily at a dose of 20 mg / kg / day.

[0062] In Example 5, dehydroepiandrosterone (DHEA) was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; additionally, the treatment drug from Example 5 was injected daily at a dose of 20 mg / kg / day.

[0063] In Example 6, dehydroepiandrosterone was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; additionally, the treatment drug from Example 6 was injected daily at a dose of 20 mg / kg / day.

[0064] In the univariate control group 1, dehydroepiandrosterone (DHEA) was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; in addition, the treatment drug from the univariate control group 1 was injected daily at a dose of 20 mg / kg / day.

[0065] In the univariate control group 2, dehydroepiandrosterone (DHEA) was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; in addition, the treatment drug from the univariate control group 2 was injected daily at a dose of 20 mg / kg / day.

[0066] In the univariate control group 3, dehydroepiandrosterone (DHEA) was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; in addition, the treatment drug of the univariate control group 3 was injected daily at a dose of 20 mg / kg / day.

[0067] In the univariate control group 4, dehydroepiandrosterone (DHEA) was injected subcutaneously at a dose of 60 mg / kg / day for 20 days; in addition, the treatment drug of the univariate control group 4 was injected daily at a dose of 20 mg / kg / day.

[0068] During the experiment, SD rats had free access to food and water.

[0069] Fasting blood glucose and fasting insulin levels were measured after 20 days, and the model group successfully constructed a polycystic ovary syndrome SD rat model.

[0070] Twenty days later, serum fasting insulin, fasting glucose, luteinizing hormone, follicle-stimulating hormone, and testosterone levels in SD rats were measured to assess endocrine function. The relative expression level of PPARγ was also measured. The average values ​​from six SD rats in each group were taken.

[0071] Figure 1 This is the result of a fasting insulin test. Figure 2 These are the results of a fasting glucose test, from Figures 1-2 As can be seen, the fasting insulin and fasting glucose levels were highest in the model group, while the fasting insulin and fasting glucose levels were lowest in the blank control group. The fasting insulin and fasting glucose levels in Example 1 to Example 6 were higher than those in the control group.

[0072] Figure 3 This is the result of the luteinizing hormone test. Figure 4 This is the result of the follicle-stimulating hormone (FSH) test. Figure 5 The results showed that, compared with the blank control group, the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone in the model group were significantly abnormal. However, the levels of LH, FSH, and testosterone in Examples 1 to 6 (Examples 1 to 6) were restored to levels close to those in the blank control group. Furthermore, the single-factor control groups using mannitol, vitamin B3, and vitamin B9 alone also restored the levels of LH, FSH, and testosterone to some extent.

[0073] Figure 6 The results show the relative expression levels of PPARγ. The results indicate that mannitol, vitamin B3, and vitamin B9 can increase the relative expression levels of PPARγ and improve endocrine function in SD rats. The combination of mannitol, vitamin B3, vitamin B9, and astragaloside IV yielded even better results.

[0074] II. Cell Experiments (1) Human ovarian granulosa cells KGN were purchased from Guangzhou Fuerbo Biotechnology Co., Ltd.

[0075] (2) In each well of the cell culture plate, seed 10 cells. 5 Cells were counted, and the time was recorded as 0 h. 100 μL of DMEM / F12 medium containing 10% fetal bovine serum was added. Treatment was then initiated in groups as follows:

[0076] The blank control group was replaced with an equal volume of sterile deionized water.

[0077] In Example 1-1, the therapeutic drug from Example 1 was added to the group, with a final concentration of 20 μg / mL.

[0078] In Example 2-1, the therapeutic drug from Example 2 was added to the group, with a final concentration of 20 μg / mL.

[0079] In Example 3-1, the therapeutic drug from Example 3 was added to the group, with a final concentration of 20 μg / mL.

[0080] In Example 4-1, the therapeutic drug from Example 4 was added to the group, with a final concentration of 20 μg / mL.

[0081] In Example 5-1, the therapeutic drug from Example 5 was added to the group, with a final concentration of 20 μg / mL.

[0082] In Example 6-1, the therapeutic drug from Example 6 was added to the group, with a final concentration of 20 μg / mL.

[0083] The treatment drug from the single-factor control group 1-1 was added to the single-factor control group 1-1, with a final concentration of 20 μg / mL.

[0084] The treatment drug from the univariate control 2-1 group was added to the univariate control 2-1 group, with a final concentration of 20 μg / mL.

[0085] The univariate control 3-1 group was given the same treatment drug as the univariate control 3-1 group, with a final concentration of 20 μg / mL.

[0086] The univariate control 4-1 group was supplemented with the treatment drug from the univariate control 4-1 group, with a final concentration of 20 μg / mL.

[0087] After culturing for 48 hours, calculate the cell viability using the following formula.

[0088] Cell viability = 100% × (number of cells surviving at 48h / number of cells surviving in the 0h control group) See results Figure 7The results showed that vitamin B3, vitamin B9, mannitol, and astragaloside IV could all kill human ovarian granulosa cells and inhibit their proliferation. The mixture of these four substances showed the best effect compared to the blank control group containing sterile deionized water.

[0089] III. Other Control Experiments To demonstrate the specificity of the combination of mannitol, vitamin B3, vitamin B9, and astragaloside IV, this invention included control experiments using other alcohols or vitamins.

[0090] (1) Human ovarian granulosa cells KGN, purchased from Guangzhou Kebai Biotechnology Co., Ltd.

[0091] (2) In each well of the cell culture plate, seed 10 cells. 5 Cells were counted, and the time was recorded as 0 h. 100 μL of DMEM / F12 medium containing 10% fetal bovine serum was added. Treatment was then initiated in groups as follows:

[0092] The blank control group was replaced with an equal volume of sterile deionized water.

[0093] In Experiment 1, the therapeutic drug from Example 1 was added to the experimental group, with a final concentration of 20 μg / mL.

[0094] In Experiment 2, the replacement drug from Example 1 was added to a final concentration of 20 μg / mL. The replacement drug in Example 1 refers to replacing mannitol in Example 1 with ethylene glycol in an equal amount.

[0095] In Experiment 3, the replacement drug from Example 1 was added to the group, with a final concentration of 20 μg / mL. The replacement drug in Example 1 refers to replacing vitamin B3 in Example 1 with vitamin B12 in an equal amount.

[0096] In Experiment 4, the replacement drug from Example 1 was added to the group, with a final concentration of 20 μg / mL. The replacement drug in Example 1 refers to replacing vitamin B3 in Example 1 with vitamin C in an equal amount.

[0097] In Experiment 5, the replacement drug from Example 1 was added to the group, with a final concentration of 20 μg / mL. The replacement drug in Example 1 refers to replacing vitamin B9 in Example 1 with vitamin B12 in an equal amount.

[0098] Group 6 of the experiment was given the replacement drug from Example 1, with a final concentration of 20 μg / mL. The replacement drug in Example 1 refers to replacing vitamin B9 in Example 1 with vitamin C in an equal amount.

[0099] In Experiment 7, the replacement drugs from Example 1 were added to a final concentration of 20 μg / mL. The replacement drugs in Example 1 were ethylene glycol and vitamins B9 and B3, respectively, replaced with vitamin C in equal amounts.

[0100] Ethylene glycol was added to Group 8 of the experiment, with a final concentration of 20 μg / mL.

[0101] Vitamin B12 was added to group 9 of the experiment, with a final concentration of 20 μg / mL.

[0102] Vitamin C was added to group 10 of the experiments, with a final concentration of 20 μg / mL.

[0103] After culturing for 48 hours, calculate the cell viability using the following formula.

[0104] Cell viability = 100% × (number of cells surviving at 48h / number of cells surviving in the blank control group at 0h) See results Figure 8 The results showed that ethylene glycol, vitamin B12, and vitamin C, when used alone, could not kill human ovarian granulosa cells. The combination of ethylene glycol, vitamin B12, and vitamin C with astragaloside IV showed effects essentially the same as the single-factor control group 1, indicating that ethylene glycol, vitamin B12, and vitamin C could not enhance the effect of astragaloside IV in killing human ovarian granulosa cells.

[0105] It should be noted that when numerical ranges are involved in this invention, it should be understood that both endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as in the embodiments, preferred embodiments are described in this invention to avoid redundancy. Although preferred embodiments of this invention have been described, those skilled in the art, once they understand the inventive concept of this invention, can make other changes and modifications to these embodiments, and all such changes and modifications fall within the scope of this invention.

[0106] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. If such modifications and variations fall within the scope of equivalents of this invention, then this invention also intends to include these modifications and variations.

Claims

1. The use of astragaloside IV and its compound preparation in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The compound consists of mannitol, vitamin B3, vitamin B9, and the mass ratio of the three is 0.5-1:0.5-1:1; the mass ratio of astragaloside IV and the compound is 1:2-4.

2. The use of astragaloside IV and its complex according to claim 1 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The mass ratio of astragaloside IV and the compound is 1:

2.

3. Use of astragaloside IV and its complex according to claim 1 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The medicine is an aqueous solution.

4. The use of astragaloside IV and its complex according to claim 3 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The concentration of the medicine is 20-60 μg / mL.

5. Use of astragaloside IV and its complex according to claim 1 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The medicine is a medicine for treating polycystic ovary syndrome in rats.

6. Use of astragaloside IV and its complex according to claim 1 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The medicine is a medicine for improving insulin level, glucose level, luteinizing hormone level, follicle-stimulating hormone level and testosterone level.

7. Use of astragaloside IV and its complex according to claim 1 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The medicine is a medicine for inhibiting the proliferation of human ovarian granulosa cells.

8. Use of astragaloside IV and its complex according to claim 1 in the preparation of a drug for treating polycystic ovary syndrome, characterized in that, The medicine takes the compound and astragaloside IV as active ingredients.

9. A therapeutic preparation for polycystic ovary syndrome, characterized by, The medicine takes astragaloside IV and the compound in claim 1 as active ingredients, and is prepared by using pharmaceutically acceptable adjuvants.

10. The therapeutic preparation for polycystic ovary syndrome according to claim 9, characterized by, The adjuvants include one or more of sodium carboxymethyl cellulose, sodium alginate, polyvinyl alcohol and polyoxyethylene.

Images